1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Bio-Techne Corporation

Bio-Techne Corporation

TECH
Bio-Techne CorporationUS flagNASDAQ Global Select
56.03
USD
-0.14
- -
8.77BMarket Cap
Bio-Techne Corporation
TECH
(NASDAQ Global Select)

Recent

price

56.03

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.81
1.95
2.13
2.11
2.42
3.05
3.35
3.77
4.29
4.72
4.83
6.01
7.05
7.23
7.35
7.74
7.78
Revenue per Share
0.74
0.76
0.76
0.76
0.75
0.73
0.7
0.51
0.84
0.64
1.5
0.91
1.73
1.81
1.07
0.47
0.7
Basic EPS, GAAP
0.72
0.83
0.82
0.69
0.83
0.81
0.86
0.86
1
1.03
1
1.99
1.79
1.38
1.5
1.63
1.73
Free Cash Flow per Basic Share
0.26
0.27
0.28
0.29
0.31
0.32
0.32
0.32
0.32
0.32
0.32
0.32
0.32
0.32
0.32
0.32
0.32
Dividend per Share
2.69
3.19
3.52
3.99
4.43
4.81
5.18
5.36
5.85
6.17
6.92
7.01
7.17
8.34
8.41
6.78
7.37
Book Value per Share
3.19
3.01
3.67
4.16
3.63
1.1
0.93
-0.55
0.23
-0.97
0.89
0.72
2.21
3.56
3.74
3.63
5.07
Tangible Book Value per Share
149
148
148
147
148
148
149
149
150
151
153
155
157
157
158
158
156
Basic Weighted Avg Shares
269
290
315
311
358
452
499
563
643
714
739
931
1,106
1,137
1,159
1,220
1,211
Sales/Revenue/Turnover
57.29
55.44
52.16
50.32
44.11
33.13
30.38
25.68
24.76
20.6
20.15
26.07
26.76
25.6
21.26
19.91
24.31
Operating Margin (%)
8
9
12
12
19
37
43
60
64
78
83
88
101
107
112
110
100
Depreciation Expense
110
112
112
113
111
108
104
76
126
96
229
140
272
285
168
73
110
Net Income, GAAP
29.83
31.93
30.74
29.94
31.26
30.12
29.16
32.04
- -
14.23
17.07
5.8
12.7
15.71
9.47
25.45
25.54
Effective Tax Rate (%)
40.8
38.73
35.71
36.24
31.01
23.82
20.94
13.51
19.62
13.46
31.04
15.08
24.61
25.1
14.5
6.02
9.05
Profit Margin (%)
184
212
311
377
443
209
200
213
319
311
414
358
430
493
458
432
535
Working Capital
- -
- -
- -
- -
7
73
92
344
339
493
411
396
302
444
407
430
276
LT Debt
502
586
674
738
795
847
879
950
1,079
1,166
1,381
1,571
1,701
1,967
2,069
1,919
2,085
Total Equity
22.41
19.96
17.72
15.2
13.93
12.08
11.3
8.65
- -
8.14
7.07
11.99
12.8
10.98
9.07
7.45
9.11
Return on Invested Capital (%)
29.41
25.71
22.6
20.3
17.69
14.93
12.76
8.07
- -
8.64
16.74
10.27
19.62
18.32
10.38
4.9
7.64
Return on Capital (%)
29.41
25.71
22.6
20.3
17.87
15.75
14.07
9.69
15.05
10.62
23.04
13.1
24.62
23.43
12.75
6.13
9.35
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
14
14
14
LT Borrowings
300
260
200
LT Finance Leases
81
77
76
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
156
156
157
Market Capitalization
8,709
9,168
8,134

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
610
637
688
Cash, Cash Equivalents & STI
145
173
210
Accounts Receivable, Net
184
185
215
Inventories
203
205
201
Total Current Liabilities
145
140
153
Payables & Accruals
96
94
99
ST Debt
14
14
14
Deferred Revenue
30
31
38

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.76%
7.12%
-7.25%
Free Cash Flow
11.32%
17.33%
8.66%
Net Income, GAAP
11.29%
-7.51%
-56.34%
Sales/Revenue/Turnover
10.67%
10.96%
5.23%
Total Cash Common Dividend
0.68%
0.6%
-0.06%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
277
273
303
306
1,159
2025
289
297
316
317
1,220
2026
287
296
311
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.32
0.17
0.31
0.26
1.07
2025
0.21
0.22
0.14
-0.11
0.47
2026
0.25
0.24
0.33
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
0.08
0.08
0.08
0.32
2025
0.08
0.08
0.08
0.08
0.32
2026
0.08
0.08
0.08
- -
- -
Similar Companies
Viva Biotech Holdings (1873.HK)
Aerovate Therapeutics, Inc. (AVTE)
Kuros Biosciences AG (0RHR.L)
Athira Pharma, Inc. (ATHA)
Futura Medical plc (FUM.L)
Ovid Therapeutics Inc. (OVID)
Business
Bio-Techne Corporation (NASDAQ: TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and supplies high-quality reagents, analytical instruments, and precision diagnostics for biotechnology research, clinical diagnostics, bioprocessing, and cell and gene therapy applications worldwide; the company operates through two primary segments, Protein Sciences, which provides biological reagents including cytokines, antibodies, immunoassays, cell selection kits, multicolor flow cytometry kits, multiplex assays, biologically active compounds, stem cell products, and proteomic analytical tools, and Diagnostics and Genomics, which offers diagnostic products such as advanced tissue-based in-situ hybridization assays for spatial genomic analysis and tissue biopsy, exosome-based molecular diagnostic assays, controls, calibrators, genetic and oncology kits, and clinical hematology controls; key brands encompass R&D Systems, Novus Biologicals, Tocris Bioscience, ProteinSimple, ACD, Asuragen, Lunaphore, and BiosPacific, with over 500,000 products in its catalog, 95% manufactured in-house, supporting customers in pharmaceutical, therapeutic, diagnostics, and life science industries across more than 34 global locations including subsidiaries in Europe, China, and Hong Kong. Founded in 1976 as Research and Diagnostic Systems and renamed Bio-Techne in 2014 following its 1981 incorporation, the company employs over 3,000 people and generated approximately $1.2 billion in net sales for fiscal 2024. Recent developments include a strategic distribution partnership with Spear Bio announced in July 2025 to expand access to SPEAR UltraDetect ultrasensitive immunoassays for neurology biomarkers such as pTau 231, pTau 217, GFAP, and Nf-L, following Bio-Techne's investment in Spear Bio's 2024 Series A funding; the divestiture of its Exosome Diagnostics business to Mdxhealth SA in August 2025 for $15 million plus royalties; licensing of AI-designed NovoBody Duo molecules from Monod Bio in November 2025 to enhance its recombinant protein portfolio; launch of the ProximityScope Assay on the BOND RX platform in October 2025 for spatial protein-protein interactions research; and an AI-powered spatial biology workflow collaboration with Nucleai in November 2025 for predictive biomarker discovery in melanoma patients.

Company News

MCPAPIChat

  • youtube.com

    TECH TITAN SUED: OpenAI CONFRONTS first-of-its-kind state legal challenge

  • seekingalpha.com

    CMB.TECH: A Stronger Shipping Platform, But Not A Cheap One

  • zacks.com

    Why Is Techne (TECH) Up 4.5% Since Last Earnings Report?

  • prnewswire.com

    Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization

  • globenewswire.com

    CMB.TECH RESULTS GENERAL MEETINGS

  • seekingalpha.com

    CMB.TECH NV (CMBT) Q1 2026 Earnings Call Transcript

  • marketbeat.com

    CMB.TECH Q1 Earnings Call Highlights

  • globenewswire.com

    CMB.TECH announces Q1 2026 results

  • seekingalpha.com

    Bio-Techne Corporation (TECH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

  • globenewswire.com

    CMB.TECH announces Q1 2026 results on 19/05/2026

  • seekingalpha.com

    Bio-Techne Corporation (TECH) Q3 2026 Earnings Call Transcript

  • zacks.com

    TECH Stock Falls on Q3 Earnings & Revenue Miss, Operating Margin Up

  • zacks.com

    Techne (TECH) Misses Q3 Earnings and Revenue Estimates

  • reuters.com

    Bio-Techne misses revenue estimates as US academic funding cuts dent demand

  • prnewswire.com

    Bio-Techne Declares Dividend

  • prnewswire.com

    Bio-Techne Releases Third Quarter Fiscal 2026 Results

  • prnewswire.com

    Bio-Techne to Present at the Bank of America Securities 2026 Global Healthcare Conference

  • zacks.com

    Bio-Techne's Q3 Earnings on Deck: What's in Store for the Stock?

  • globenewswire.com

    CMB.TECH publishes its annual report & Form 20-F and announces general meetings of 21 May 2026

  • defenseworld.net

    Bio-Techne Corp (NASDAQ:TECH) Receives $72.77 Consensus PT from Analysts